The contribution of kinins to the beneficial effects in cardiovascular risk reductions remains unclear. In this context, the present study examined whether the þ 9 bp/À9 bp polymorphism in bradykinin type 2 receptor gene, predicts hypertension risk in a large urban Brazilian population. Our finding indicated that the À9 bp allele may contribute to hypertension because of increased diastolic pressure.
Bradykinin, acting through its type 2 receptor (B 2 R), exerts significant vascular protective effects including the stimulation of microangiogenesis, inhibition of smooth muscle cell growth, coronary vasodilatation, increased local nitric oxide synthesis and anti-thrombotic actions. 1 The cardioprotective effects of angiotensin-converting enzyme inhibitors derive in part from the capacity of these agents to enhance the beneficial contributions of the bradykinin and B 2 R. 1 The role of bradykinin in health and disease has been highlighted by recent studies that have identified associations between genetic variations in the B 2 R and significantly higher coronary risk attributable to hypertension 2 and decreased regression of left ventricular mass in response to antihypertensive treatment. 3 These studies have focused in a functional polymorphism described in exon 1 of the bradykinin type 2 receptor gene (BDKRB2), 4 in which the presence ( þ 9 bp) rather than the absence (À9 bp) of a 9-base pair sequence was associated with lower gene transcriptional activity. 5, 6 If raised kinin activity is indeed vascular protective, we would anticipate that low bradykinin receptor activity, as marked by the þ 9 bp allele, would be associated with increased cardiovascular risk. According with these facts, the present study aimed to evaluate whether þ 9 bp/À9 bp polymorphism was associated with blood pressure (BP) variation on an admixture urban population.
Our study was based on a cross-sectional design in urban population of Vitó ria City, Brazil. 7 A sample of 2044 participants of either gender, 25 to 64 years of age, was chosen according to the nearest birthday after a random selection of domiciles. Of the 2044 participants invited, 1570 individuals attended the clinic visit and were further evaluated for: anthropologic indices, ethnicity, BP, lipid profile and glucose. This study was approved by the Committee for research on Human Subjects of the Heart Institute/InCor and informed consents were obtained from all participants. Genomic DNA was obtained from leukocytes, in a sample of whole blood, according to standard techniques. 8 Genetic analysis of þ 9 bp/À9 bp polymorphism was realized by PCR technique. 9 Quality control for these assays was assessed by randomly selecting 10% samples to be re-genotyped by two independent technicians. Anthropologic, clinical and genetic data were analysed using the SPSS 13.0 (Chicago, IL, USA). Statistical analysis included descriptive statistics, odds ratio (OR) with 95% confidence interval (CI), and logistic regression analysis. Univariate and multivariate logistic regression analyses were employed to assess the relationship between hypertension status and þ 9 bp/À9 bp polymorphism with adjustment for the effects of confounding phenotypes. Quantitative variables were expressed as the mean ± s.d., and P-values o0.05 were considered statistically significant.
In the overall population, allelic frequencies ( þ 9 bp allele ¼ 52.2%; À9 bp allele ¼ 47.8%) and genotypic frequencies (27.5% for þ 9 bp/ þ 9 bp; 49.5% for þ 9 bp/À9 bp and 23.1% for À9 bp/À9 bp) were in accordance with the Hardy-Weinberg equilibrium (w 2 ¼ 0.108; P ¼ 0.742). Anthropologic, clinical and laboratorial data were stratified by genotypes (Table 1) . Results from descriptive analysis indicated an increased body mass index (P ¼ 0.039) and higher frequency of obesity (P ¼ 0.029) among heterozygotes and þ 9 bp homozygotes, whereas elevated frequency of hypertension (P ¼ 0.016) was observed among heterozygotes and À9 bp homozygotes. All other baseline characteristics were independent of the genotype (P40.05). Comparative analysis failed to indicate a significant difference between genotype groups and BP phenotypes (SBP: P ¼ 0.372; DBP: P ¼ 0.245). However, there was a slight tendency towards increased BP phenotypes in À9 bp allele carries. To confirm this observation, we evaluated the dominant ( þ 9 bp/À9 bp plus À9 bp/À9 bp versus þ 9 bp/ þ 9 bp) and recessive ( þ 9 bp/À9 bp plus þ 9 bp/ þ 9 bp versus À9 bp/À9 bp) models of action for the -9 bp allele. According to these analyses hypertension risk was 36% in -9 bp carriers as compared with the þ 9 bp allele homozygote carrier. The À9 bp allele also contributed to increased diastolic (Table 1) . Earlier studies already associated the þ 9 bp with decreased BDKRB2 transcriptional activity, 5 an increased systolic BP, 10 and an elevated prevalence of that allele in hypertensives compared with a normotensive population. 11 These data taken together suggest a pathophysiologic mechanism by which the bradykinin type 2 receptor contributes to the development of hypertension. In the present report, we did not confirm this presumed association, suggesting that the þ 9 bp variant of BDKRB2 might not confer susceptibility to hypertension in the evaluated population. In contrast, an association among À9 bp allele, hypertension risk, and increase DBP was observed in this sample of the Brazilian population. Our controversial data leave the question open of whether the þ 9 bp/À9 bp polymorphism has other functional abnormalities unknown or is a reflex of additional genetic variables and/or environmental factor interactions that were not evaluated in this and on earlier studies. In this context, further functional studies and comparative analysis involving other polymorphisms in BDKRB2 are required to elucidate the issue. 
SR

